Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/16/2025 | Outperform | William Blair | |
10/13/2025 | $9.00 | Buy | H.C. Wainwright |
8/15/2025 | $9.00 | Outperform | Robert W. Baird |
6/6/2025 | $10.00 | Outperform | Oppenheimer |
5/22/2025 | $7.00 | Buy | BTIG Research |
12/2/2024 | $10.00 | Outperform | Leerink Partners |
4 - Climb Bio, Inc. (0001768446) (Issuer)
3 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. "We are thrilled to welcome Adam and Ashley to the Climb Bio leadership team," said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio. "Their addition comes at an important time in our company's growth as we execute our clinical development plans and continue to drive
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for budoprutug, anti-CD19 monoclonal antibody, support potential for therapeutic benefit in primary membranous nephropathy (pMN) WELLESLEY HILLS, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the upcoming presentation of CLYM116 preclinical data and published budoprutug pMN Phase 1b long-term outcome data at the 2025 American Society
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci
8-K - Climb Bio, Inc. (0001768446) (Filer)
8-K - Climb Bio, Inc. (0001768446) (Filer)
8-K - Climb Bio, Inc. (0001768446) (Filer)
William Blair initiated coverage of Climb Bio with a rating of Outperform
H.C. Wainwright initiated coverage of Climb Bio with a rating of Buy and set a new price target of $9.00
Robert W. Baird initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $9.00
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight
SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)